Key Stats for IDEXX Laboratories Stock
- 52-Week Range: $507 to $770
- Current Price: $562
- Street Mean Target: $709
- Street High Target: $805
- Analyst Consensus: 5 Buys / 4 Outperforms / 5 Holds / 1 Underperform
- TIKR Model Target (December 2030): $883
IDEXX Laboratories Raises Full-Year Guidance After a 14% Revenue Beat in Q1 2026
IDEXX Laboratories (IDXX) reported Q1 2026 revenue of $1.14 billion, up 14% year over year, topping analyst estimates of $1.11 billion, while raising full-year revenue and profit guidance following the May 5 results.
The beat was not a margin story or a one-quarter fluke.
CAG Diagnostics recurring revenue, the engine that powers everything else at IDEXX, grew 11% organically in Q1, including nearly 11% in the U.S. and approximately 12% internationally, despite U.S. same-store clinical visits declining 1% in the period.
That 1,100-basis-point gap between visit declines and recurring revenue growth is the number that matters.
CFO Andrew Emerson attributed it directly to diagnostic frequency and utilization expanding per visit: “We’re seeing the diagnostic care protocols really continue to play out positively from that perspective.”
IDEXX also placed 1,100 inVue Dx analyzers in Q1, tracking toward its full-year target of 5,500 units, with new CEO Mike Erickson confirming the installed base is already generating revenue per box comfortably within the $3,500 to $5,500 target band, including only ear cytology and blood morphology, before Fine Needle Aspirate rolls out at full volume in the second half.
Cancer Dx momentum accelerated in the quarter, with over 7,500 practices ordering since launch and approximately 20% of volume coming from non-primary IDEXX reference lab accounts, which Erickson flagged as a structural customer acquisition mechanism for the lab business.
IDEXX raised its full-year revenue guidance to $4.68 billion to $4.76 billion, up $42 million at midpoint, and lifted EPS guidance to $14.45 to $14.90, up $0.13 at midpoint.
Analysts Raised Targets After Q1, But IDEXX Laboratories Stock Still Trades 21% Below Street Mean
The thesis running through Wall Street after Q1 is not a visit recovery play.
It is a diagnostic frequency compounding story: IDEXX’s revenue grows structurally through instrument placements, menu expansion, and increased testing per visit, regardless of whether total visit volumes are positive.
Street consensus on revenue sits at $1.20 billion for Q2 2026, implying around 8% year-over-year growth even against a tougher comparable, with full-year consensus tracking toward the raised guidance midpoint.
EPS estimates for Q2 stand at $3.94, up roughly 14% year over year, sustained by the same operating leverage that produced 15% comparable EPS growth in Q1.
Analyst coverage currently shows 5 Buys, 4 Outperforms, 5 Holds, 1 Underperform, with a mean price target of $709 and a street high of $805.
The mean target implies around 26% upside from the current price of $562.
Morgan Stanley’s Erin Wright reiterated Buy after the quarter and raised her price target to $805, the highest on the street.
Jefferies also issued a Buy following results.
Stifel’s Jon Block lowered his target to $675 from $775 but maintained Buy, flagging that inVue Dx is not the single swing factor for guidance, with international utilization, Cancer Dx pull-through, and diagnostic frequency each playing independent roles.
BofA lowered its target to $660 from $790 but maintained Neutral, framing the Q1 beat as “demonstrating” the platform’s resilience while pointing to the visit headwind as the ongoing drag.
The split reflects a genuine disagreement: bulls see the visit softness as a macro overhang that masks structural diagnostics growth already happening; bears see the valuation as pricing in a recovery that could stall if consumer spending on wellness visits does not improve.
The catalyst to watch is the FNA full-volume ramp in the second half, which Erickson said will move inVue Dx from controlled to unconstrained launch posture, the moment that resolves whether revenue per box trends toward the upper end of the $3,500 to $5,500 band.
TIKR’s $883 Target on IDEXX Laboratories Stock and the Platform Assumption Behind It
TIKR’s mid-case values IDEXX Laboratories at approximately $883 by December 2030, implying around 57% total return from the current price of $562, or roughly 11% annualized over 4.5 years.
The case for that target begins with the same revenue compounding already visible in the Q1 data.
IDEXX grew CAG Diagnostics recurring revenue 11% organically in Q1 despite a 1% visit decline, a result that Wall Street’s consensus $1.20 billion Q2 revenue estimate, around 8% growth, treats as the floor rather than the ceiling heading into the second half.
TIKR’s mid-case assumes roughly 8% annual revenue growth through the forecast period, a rate the Q1 print and the raised full-year guidance already support.
The second pillar is the inVue Dx FNA ramp, which Erickson confirmed will reach full unconstrained volume in the second half of 2026, an event the analyst consensus has already embedded in the Q2 and second-half estimates that underpin the forward EPS trajectory anchoring this target.
Should You Invest in IDEXX Laboratories, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDEXX Laboratories stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX Laboratories alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IDXX stock on TIKR for Free →
Why is IDEXX Laboratories stock down in 2026?
IDEXX Laboratories stock is down roughly 17% year to date despite strong Q1 results, with the selloff reflecting investor concern over declining U.S. clinical visit trends, which fell 1% in Q1, even as recurring diagnostics revenue grew 11% organically in the same period.
